<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2019.95096</article-id><article-id pub-id-type="publisher-id">ACM-30275</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20190500000_98867592.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  胰腺癌治疗的研究进展
  Research Progress on the Treatment of Pancreatic Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>君璞</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>辉</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>严</surname><given-names>俊</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>周</surname><given-names>文策</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>兰州大学第一临床医学院，甘肃 兰州</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>09</day><month>05</month><year>2019</year></pub-date><volume>09</volume><issue>05</issue><fpage>638</fpage><lpage>644</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    胰腺癌是恶性程度极高的消化道肿瘤之一，其在全球的发病率和死亡率均在逐年升高。目前临床上治疗胰腺癌的方式主要包括手术切除、放化疗，由于胰腺癌发病隐匿、病情进展快、恶性程度高等特点，患者一经发现多处于癌症的中晚期，丧失手术机会，导致患者5年生存率不足6%。为延长患者生存时间，积极探索有效的治疗方法是目前胰腺癌亟待解决的问题。近年来，随着医疗事业的快速发展，胰腺癌的治疗方法从常规的手术、放化疗到生物碱药物治疗、基因治疗、免疫治疗等。本文就目前胰腺癌的治疗方式作一概述。
    Pancreatic cancer is one of the most malignant tumors of the digestive tract, and its global mor-bidity and mortality are increasing year by year. At present, the clinical treatment of pancreatic cancer mainly includes surgical resection, radiotherapy, chemotherapy, and combination of radi-otherapy and chemotherapy. Due to the concealed disease of pancreatic cancer, the disease pro-gresses rapidly, and the degree of malignancy is high. Once the patient is found to be in the middle and late stage of cancer, the operation is lost. Opportunities lead to a 5-year survival rate of less than 6%. In order to prolong the survival time of patients, actively exploring effective treatment methods is an urgent problem to be solved in pancreatic cancer. In recent years, with the rapid development of medical services, the treatment of pancreatic cancer has ranged from conventional surgery, radiotherapy and chemotherapy to alkaloid drug therapy, gene therapy, and immuno-therapy. This article provides an overview of current treatments for pancreatic cancer. 
  
 
</p></abstract><kwd-group><kwd>胰腺癌，治疗，综述, Pancreatic Cancer</kwd><kwd> Treatment</kwd><kwd> Review</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>胰腺癌治疗的研究进展<sup> </sup></title><p>王君璞<sup>1</sup>，张辉<sup>1,2</sup>，严俊<sup>1,2</sup>，周文策<sup>1,2 *</sup></p><p><sup>1</sup>兰州大学第一临床医学院，甘肃 兰州</p><p><sup>2</sup>兰州大学第一医院，普外二科，甘肃 兰州</p><disp-formula id="hanspub.30275-formula34"><graphic xlink:href="//html.hanspub.org/file/2-1570911x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2019年4月25日；录用日期：2019年5月13日；发布日期：2019年5月20日</p><disp-formula id="hanspub.30275-formula35"><graphic xlink:href="//html.hanspub.org/file/2-1570911x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>胰腺癌是恶性程度极高的消化道肿瘤之一，其在全球的发病率和死亡率均在逐年升高。目前临床上治疗胰腺癌的方式主要包括手术切除、放化疗，由于胰腺癌发病隐匿、病情进展快、恶性程度高等特点，患者一经发现多处于癌症的中晚期，丧失手术机会，导致患者5年生存率不足6%。为延长患者生存时间，积极探索有效的治疗方法是目前胰腺癌亟待解决的问题。近年来，随着医疗事业的快速发展，胰腺癌的治疗方法从常规的手术、放化疗到生物碱药物治疗、基因治疗、免疫治疗等。本文就目前胰腺癌的治疗方式作一概述。</p><p>关键词 :胰腺癌，治疗，综述</p><disp-formula id="hanspub.30275-formula36"><graphic xlink:href="//html.hanspub.org/file/2-1570911x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/2-1570911x8_hanspub.png" /> <img src="//html.hanspub.org/file/2-1570911x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>癌症目前是全球第二大致人死亡的原因，胰腺癌是消化系统常见的肿瘤，根据美国癌症协会2018年的数据显示，死于胰腺癌的人数已达到44,430人 [<xref ref-type="bibr" rid="hanspub.30275-ref1">1</xref>] 。由于胰腺癌病情发展迅速，早期诊断困难，患者一经发现大多丧失手术的机会 [<xref ref-type="bibr" rid="hanspub.30275-ref2">2</xref>] 。因而，具有极低的存活率和较差治疗率的胰腺癌仍然是生物医学和临床领域所面临的最具挑战性的问题。如何提高胰腺癌患者远期的生存率及改善患者的预后目前已经成为亟待攻克的问题。本文结合相关的研究，就目前有关胰腺癌的治疗作一简要述评。</p></sec><sec id="s4"><title>2. 胰腺癌的发病诱因</title><p>胰腺癌的发生和很多因素有关，相关遗传背景、生活习惯、基础的疾病等。吸烟产生的烟雾中，会产生很多的致癌物质，吸烟者和经常处于烟雾环境中的人，都不同程度增加了患胰腺癌的风险 [<xref ref-type="bibr" rid="hanspub.30275-ref3">3</xref>] 。肥胖，研究人员发现肥胖患者的体内会更多的表达精氨酸酶，这种酶会间接的促使癌细胞的生长。另外一项研究中，研究者对350例胰腺癌病例进行分析，BMI ≥ 30 kg/m<sup>2</sup>的个体患胰腺癌的风险要高于BMI &lt; 23 kg/m<sup>2</sup>的患者，RR值1.72 (95%CI：1.19至2.48)，肥胖增加了患胰腺癌的风险 [<xref ref-type="bibr" rid="hanspub.30275-ref4">4</xref>] 。没有直接证据表明饮酒会导致胰腺癌的发生率增加，美国一个前瞻性研究表明，在不吸烟的情况下，每日饮酒3杯或3杯以上，会增加胰腺癌的死亡率 [<xref ref-type="bibr" rid="hanspub.30275-ref5">5</xref>] 。另有研究表明，胰腺炎的疾病史构成了发生胰腺癌的重要危险因素 [<xref ref-type="bibr" rid="hanspub.30275-ref6">6</xref>] 。II型糖尿病是胰腺癌的又一个危险因素，长期患有糖尿病的患者其发生胰腺癌的风险会增加 [<xref ref-type="bibr" rid="hanspub.30275-ref7">7</xref>] ，癌症患者由于服用化疗药物的影响又易导致糖尿病的发生 [<xref ref-type="bibr" rid="hanspub.30275-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.30275-ref9">9</xref>] 。美国Fan等 [<xref ref-type="bibr" rid="hanspub.30275-ref10">10</xref>] 的一项研究表明，在分析361例胰腺腺病人患者和对照人群口腔病原体，最终发现口腔携带有牙龈卟啉单胞菌和放线杆菌的与胰腺癌的高风险相关。</p></sec><sec id="s5"><title>3. 胰腺癌的常规治疗方式</title><sec id="s5_1"><title>3.1. 手术治疗</title><p>外科根治性手术切除胰腺肿瘤，是临床上治愈胰腺癌的最主要的手段，但由于胰腺癌早期症状不明显，大约只有20%的患者被认为是可切除的。有研究证实，如果能尽早的发现胰腺早期肿瘤切除病灶，能够延长患者的生命5年的术后生存率将会大大的提高。于文滨 [<xref ref-type="bibr" rid="hanspub.30275-ref11">11</xref>] 对60例行胰十二指肠切除术治疗的胰腺癌患者进行分析，除外死亡3例，治疗出院57例，其中可切除病例的中位生存期15~19个月，5年生存率大约在20%。有关可行外科手术治疗的主要手术方式，有标准根治术和扩大清扫范围的根治术，有学者提出扩大淋巴结的清扫范围，清除了较多的淋巴结，可以降低并发症发生率，能提高患者中位生存率，对患者是有益的 [<xref ref-type="bibr" rid="hanspub.30275-ref12">12</xref>] 。Reddy等 [<xref ref-type="bibr" rid="hanspub.30275-ref13">13</xref>] 的研究发现，扩大清扫组和标准清扫组相比，并不能显著延长患者生存期，病死率也无明显差异。因此，Pedrazzoli [<xref ref-type="bibr" rid="hanspub.30275-ref14">14</xref>] 认为，我们仍然缺乏足够的数据来表明哪个术氏患者可以受益更多。但对于中晚期胰腺癌患者，肿瘤已经发生了转移扩散，导致无法行根治性手术，只能评估患者的年龄、身体状态，恰当有效的选择姑息性手术，能解除患者的梗阻、黄疸等不适症状，也会提高患者的生活质量。</p></sec><sec id="s5_2"><title>3.2. 化学治疗</title><p>虽然化疗不能像手术切除那样可以有效的治疗胰腺肿瘤，但仍可以提高患者生存质量，改善预后。目前临床上常用的单一化疗药物有氟尿嘧啶、丝裂霉素、异环磷酰胺等，对胰腺癌的敏感性较差，氟尿嘧啶和丝裂霉素，有效率仅仅接近24%。联合化疗治疗胰腺癌相比单一化疗药物治疗，其效果更好，常用的化疗方案有氟尿嘧啶、阿霉素和丝裂霉素(FAM)；链霉素、丝裂霉素和氟尿嘧啶(SMF)；氟尿嘧啶、阿霉素和顺铂(FP)等 [<xref ref-type="bibr" rid="hanspub.30275-ref15">15</xref>] 。Glenwigga等 [<xref ref-type="bibr" rid="hanspub.30275-ref16">16</xref>] 在使用SMF的化疗方案治疗晚期胰腺腺癌，患者存活时间明显比同期其他的胰腺癌患者(7.5个月VS 3个月)要长，且SMF的副作用也较低。吉西他滨，是一种新型嘧啶拮抗剂，在许多肿瘤中发挥作用，是治疗胰腺癌的一类化疗药物 [<xref ref-type="bibr" rid="hanspub.30275-ref17">17</xref>] 。患者对吉西他滨的反应更灵敏，能改善症状并延长生存期。但也容易产生耐药性，总体治疗效果欠佳 [<xref ref-type="bibr" rid="hanspub.30275-ref18">18</xref>] 。有研究也证实采用吉西他滨+卡培他滨，吉西他滨 + 顺铂 + 5–氟尿嘧啶，吉西他滨 + 厄洛替尼等的治疗方案效果会更好 [<xref ref-type="bibr" rid="hanspub.30275-ref19">19</xref>] 。</p></sec><sec id="s5_3"><title>3.3. 放射治疗</title><p>放疗在胰腺癌治疗中的作用存在很大的争议。X线照射对胰腺癌的治疗，最早开始于20世纪，由于X射线的深度量低，胃肠反应大，疗效差等一系列问题的出现，而逐渐被淘汰。后随着科技的发展，探索其他的有效的放疗方案，以最大限度地对肿瘤进行局部治疗，越来越受到人们的关注。Patrick的研究表明，在局部不可行切除术的胰腺癌患者，放射治疗加用吉西他滨的治疗可提高总体生存率，且产生的毒副作用相对较少 [<xref ref-type="bibr" rid="hanspub.30275-ref20">20</xref>] 。立体定向体部放疗(stereotactic body radiotherapy SBRT)，SBRT是在立体定向放射外科(SRS)的基础上发展而来，能够经过计算机运算后用γ-刀和X线的照射，使目标靶区接受高剂量照射，而使周围的正常组织接受很低射线的照射的技术 [<xref ref-type="bibr" rid="hanspub.30275-ref21">21</xref>] 。但Schellenberg的研究 [<xref ref-type="bibr" rid="hanspub.30275-ref22">22</xref>] 在纳入16例胰腺癌患者，均接受了吉西他滨联合SBRT治疗，患者分别于SBRT术后4~6周、10~12周及每3个月进行评估。最终证实，SBRT联合吉西他滨治疗与常规放化疗的生存率却相当，肿瘤的局部控制良好，但增加了十二指肠溃疡的发生率。目前有关SBRT的临床研究国内外仅有10余年，有关照射剂量、时间等一些问题还处于探索阶段。</p></sec></sec><sec id="s6"><title>4. 胰腺癌新辅助治疗</title><sec id="s6_1"><title>4.1. 基因治疗</title><p>基因治疗一直是肿瘤学研究的热点，也是极具发展前景可能攻克癌症的一种新型治疗手段。肿瘤的发生发展是促癌基因的表达以及抑癌基因的失活相互作用的结果。基因治疗的首要步骤是用载体把目的基因转移到靶细胞中，常用于胰腺癌的载体包括：腺病毒、慢病毒、脂质体及裸DNA等。不完全复制及选择性复制的腺病毒现已应用于胰腺癌的基因治疗 [<xref ref-type="bibr" rid="hanspub.30275-ref23">23</xref>] 同时可以把失去功能的抑癌基因替换成功能正常的抑癌基因，目前在研究中的基因有p53，p16，INK4a，CDKN2A和SMAD4E等 [<xref ref-type="bibr" rid="hanspub.30275-ref24">24</xref>] 。另外CRISPR/Cas9基因编辑技术的诞生，极大的推动了基因肿瘤治疗的发展。2014年麻省理工学院的科研人员率先利用CRISPR-Cas9基因编辑系统。给小鼠注射含有Cas9和sgRNAs的CRISPR质粒从而诱发了肿瘤，科研人员随即提取组织进行测序，结果表明肿瘤细胞内存在P53及PTEN的突变，同时研究人员在尾静脉注射带有β-catenin靶点的CRISPR系统，实现了小鼠的肝脏细胞β-catenin的点突变 [<xref ref-type="bibr" rid="hanspub.30275-ref25">25</xref>] [<xref ref-type="bibr" rid="hanspub.30275-ref26">26</xref>] 。这项技术已经实现了直接在基因水平的编辑，期待其在肿瘤基因治疗中发挥更大的作用。</p></sec><sec id="s6_2"><title>4.2. 免疫治疗</title><p>免疫治疗目前多采用的是疫苗接种。疫苗制备收集胰腺癌病人的肿瘤细胞，体外培养，运用载体导入炎症刺激因子的基因，后将细胞制成疫苗，并注射人体内产生对肿瘤的特异性反应。Jaffee [<xref ref-type="bibr" rid="hanspub.30275-ref27">27</xref>] 等为了确定胰腺肿瘤疫苗的安全性和诱导抗肿瘤免疫反应的能力，研究者用异基因粒细胞-巨噬细胞集落刺激因子(GM-CSF)分泌的肿瘤疫苗，对胰腺腺癌患者进行了一期试验。3名患者接受1 &#215; 107个疫苗细胞，3名患者接受5 &#215; 107个疫苗细胞，3名患者接受10 &#215; 107个疫苗细胞。最终患者没有遇到因剂量过大产生的毒性反应。同时疫苗接种接受量 ≥ 10 &#215; 107的三名患者对自体肿瘤细胞的迟发型超敏反应(DTH)反应增加，诊断胰腺癌后无疾病存活时间也相对增长，证明同种异体GM-CSF分泌肿瘤疫苗对胰腺癌患者是安全的。另有研究者Bernhardt [<xref ref-type="bibr" rid="hanspub.30275-ref28">28</xref>] 在不可切除的胰腺癌患者中，进行I/II期的研究来检验端粒酶肽疫苗GV1001接种的安全性，耐受性和免疫原性。最终在38名参与评估的患者中24名观察到免疫应答，中等剂量组的比例最高(75%)，且中等剂量组的中位生存期可达8.6个月，因此表明GV1001具有免疫原性并且可以安全使用。肿瘤疫苗的产生可为胰腺癌患者提供新的治疗选择。</p></sec><sec id="s6_3"><title>4.3. 冷冻疗法</title><p>1963年，Cooper率先采用液氮治疗恶性肿瘤 [<xref ref-type="bibr" rid="hanspub.30275-ref29">29</xref>] 。冷冻治疗较多的用于前列腺癌的术后复发的补救。患者5年的生存率约59% [<xref ref-type="bibr" rid="hanspub.30275-ref30">30</xref>] 。李波等 [<xref ref-type="bibr" rid="hanspub.30275-ref31">31</xref>] 44例病案报导。对近7年44例无法切除的胰腺癌进行冷冻治疗，胰腺癌冷冻手术附加内引流术(胆囊或胆管空肠吻合 + 胃空肠吻合术)共有28例，联合区域性灌注化疗20例，联合腹腔神经丛无水乙醇区域性注射镇痛20例。大多数病人(77.4%, 34/44)行空肠造瘘术，结果全组无手术死亡。术后腹、背部疼痛缓解率89.47% (34/38)。多数肿瘤有不同程度缩小，血CA199下降，血淀粉酶1周内轻度升高，但无胰腺炎表现。34例获得随访，中位生存期14个月，1年生存率为57.5%。Kovach [<xref ref-type="bibr" rid="hanspub.30275-ref32">32</xref>] 等对9例无法切除的癌症患者进行了冷冻手术，得出患者术后对疼痛有良好的控制，出院时能够正常饮食。因此，冰冻手术对无法行手术治疗的胰腺癌患者，是一种新型治疗手段。</p></sec><sec id="s6_4"><title>4.4. 生物碱类药物治疗</title><p>生物碱多是来源于动植物和中草药的一类碱性化合物。近年来的研究发现，生物碱中的紫杉醇类、长春碱类、苦参碱类、喜树碱类等其他种类的生物碱能够调控多种信号通路来抑制细胞的增殖及侵袭，控制细胞周期、诱导细胞出现凋亡和自噬等作用。Ma [<xref ref-type="bibr" rid="hanspub.30275-ref33">33</xref>] 等的研究发现，苦参碱能降低了由Wnt信号传导途径介导的MT1-MMP的表达，进而可以在抑制胰腺癌细胞HPAC或Capan-1的增殖、侵袭和迁移发挥作用。另外在胰腺癌细胞(BxPC3, MiaPaCa2 and PANC-1)研究中发现，粉防己碱能够增加p21 (WAF1/CIP1)和p27 (KIP1)表达水平，并降低cyclin D1和pRb蛋白的水平，使胰腺癌细胞失调的细胞周期恢复正常，抑制肿瘤的生长 [<xref ref-type="bibr" rid="hanspub.30275-ref34">34</xref>] 。同时生物碱类也可以和吉西他滨联合起来使用，Von Hoff [<xref ref-type="bibr" rid="hanspub.30275-ref35">35</xref>] 等在nab–紫杉醇联合吉西他滨的在晚期胰腺癌患者1~2期试验中，共有861名患者被随机分配到nab–紫杉醇加吉西他滨(431名患者)或吉西他滨(430名)组，结果证实nab–紫杉醇–吉西他滨组的中位总生存期为8.5个月，而吉西他滨组为6.7个月。nab–紫杉醇–吉西他滨组的存活率为35%，而吉西他滨组的存活率为9%。即nab–紫杉醇联合吉西他滨能明显改善患者总体存活率。目前，生物碱已成为国内外研究的热点，具有临床一线抗癌药物的潜力。</p></sec><sec id="s6_5"><title>4.5. 分子靶向治疗</title><p>随着分子生物学的快速发展，分子靶向药物也开始应用于胰腺癌的治疗。由于胰腺肿瘤常常过度表达人类表皮生长因子受体1 (HER1/EGFR)，这与预后差有关。像厄洛替尼能够作用于EGFR，阻止络氨酸激酶磷酸化，进而诱导肿瘤细胞的凋亡。有证据表明在使用厄洛替尼 + 吉西他滨治疗中晚期胰腺癌，能延长患者的生存期 [<xref ref-type="bibr" rid="hanspub.30275-ref36">36</xref>] 。同时，Moore [<xref ref-type="bibr" rid="hanspub.30275-ref37">37</xref>] 等在加拿大国家癌症研究所临床试验小组的III期试验，共有569名胰腺癌患者参与其中。其中厄洛替尼+吉西他滨组的治疗分析的总生存率比吉西他滨组延长，风险比(HR)为0.82 (95% CI，0.69至0.99；P = 0.038，中位数6.24月v 5.91个月)。厄洛替尼 + 吉西他滨组的一年生存率也更高(23% vs 17%; P = 0.023)。虽然厄洛替尼 + 吉西他滨的一些副作用发生率较高，但大多数为1级或2级。这项随机III期试验表明厄洛替尼 + 吉西他滨的治疗胰腺癌效果更好。此外，有关VEGF抑制剂贝伐珠单抗、索拉非尼等药物还处于临床试验阶段。</p></sec></sec><sec id="s7"><title>5. 小结和展望</title><p>胰腺癌是严重危害人类健康的疾病，对于满足手术指征的胰腺癌患者，首选根治性切除术。对于已经失去手术机会的患者，在采用传统放化疗的基础上，可以辅采用生物碱治疗、基因治疗、靶向治疗、免疫治疗等一系列的方法以延长患者生存时间及提高生活质量。同时患者应该从自身做起戒烟戒酒、合理膳食、控制体重并加强锻炼。目前随着胰腺癌基础研究的不断深入，诊断技术的日益提高，相信不久的将来各种针对胰腺癌治疗的药物及措施会相继面世，胰腺癌治疗会进入有效化、精准化及个体化的新时代。</p></sec><sec id="s8"><title>基金项目</title><p>甘肃省科技厅重点研发计划(17YF1FA128)；兰州大学第一医院院内基金项目(ldyyyn2015-18)。</p></sec><sec id="s9"><title>文章引用</title><p>王君璞,张 辉,严 俊,周文策. 胰腺癌治疗的研究进展Research Progress on the Treatment of Pancreatic Cancer[J]. 临床医学进展, 2019, 09(05): 638-644. https://doi.org/10.12677/ACM.2019.95096</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.30275-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Siegel, R.L., Miller, K.D. and Jemal, A. (2018) Cancer Statistics, 2018. CA: A Cancer Journal for Clinicians, 68, 7-30.  
&lt;br&gt;https://doi.org/10.3322/caac.21442</mixed-citation></ref><ref id="hanspub.30275-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Ferlay, J., Soerjomataram, I., Dikshit, R., et al. (2015) Cancer Incidence and Mortality Worldwide: Sources, Methods and Major Patterns in GLOBOCAN 2012. International Journal of Cancer, 136, E359-E386.  
&lt;br&gt;https://doi.org/10.1002/ijc.29210</mixed-citation></ref><ref id="hanspub.30275-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Bosetti, C., Lucenteforte, E., Silverman, D.T., et al. (2012) Cigar and Pipe Smoking, Smokeless Tobacco Use and Pancreatic Cancer: An Analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4). Annals of Oncology, 23, 1880-1888. &lt;br&gt;https://doi.org/10.1093/annonc/mds491</mixed-citation></ref><ref id="hanspub.30275-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Michaud, D.S., Giovannucci, E., Willett, W.C., et al. (2001) Physical Activity, Obesity, Height, and the Risk of Pancreatic Cancer. JAMA, 286, 921-929. &lt;br&gt;https://doi.org/10.1001/jama.286.8.921</mixed-citation></ref><ref id="hanspub.30275-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Gapstur, S.M., Jacobs, E.J., Deka, A., et al. (2011) Association of Alcohol Intake with Pancreatic Cancer Mortality in Never Smokers. Archives of Internal Medicine, 171, 444-451. &lt;br&gt;https://doi.org/10.1001/archinternmed.2010.536</mixed-citation></ref><ref id="hanspub.30275-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Bansal, P. and Sonnenberg, A. (1995) Pancreatitis Is a Risk Factor for Pancreatic Cancer. Gastroenterology, 109, 247-251. &lt;br&gt;https://doi.org/10.1016/0016-5085(95)90291-0</mixed-citation></ref><ref id="hanspub.30275-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Huxley, R., Ansary-Moghaddam, A., Berrington de González, A., et al. (2005) Type-II Diabetes and Pancreatic Cancer: A Meta-Analysis of 36 Studies. British Journal of Cancer, 92, 2076-2083. &lt;br&gt;https://doi.org/10.1038/sj.bjc.6602619</mixed-citation></ref><ref id="hanspub.30275-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Giovannucci, E., Harlan, D.M., Archer, M.C., et al. (2010) Diabetes and Cancer: A Consensus Report. CA: A Cancer Journal for Clinicians, 60, 207-221. &lt;br&gt;https://doi.org/10.3322/caac.20078</mixed-citation></ref><ref id="hanspub.30275-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Permuth Wey, J. and Egan, K.M. (2009) Family History Is a Significant Risk Factor for Pancreatic Cancer: Results from a Systematic Review and Meta-Analysis. Familial Cancer, 8, 109-117.  
&lt;br&gt;https://doi.org/10.1007/s10689-008-9214-8</mixed-citation></ref><ref id="hanspub.30275-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Fan, X., Alekseyenko, A.V., Wu, J., et al. (2018) Human Oral Microbiome and Prospective Risk for Pancreatic Cancer: A Population-Based Nested Case-Control Study. Gut, 67, 120-127. &lt;br&gt;https://doi.org/10.1136/gutjnl-2016-312580</mixed-citation></ref><ref id="hanspub.30275-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">于文滨. 60例胰十二指肠切除手术治疗胰腺癌临床分析[J]. 中国现代药物应用, 2013, 7(5): 49-50.</mixed-citation></ref><ref id="hanspub.30275-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Ishikawa, O., Ohhigashi, H., Sasaki, Y., et al. (1988) Practical Usefulness of Lymphatic and Connective Tissue Clearance for the Carcinoma of the Pancreas Head. Annals of Surgery, 208, 215-220.  
&lt;br&gt;https://doi.org/10.1097/00000658-198808000-00014</mixed-citation></ref><ref id="hanspub.30275-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Reddy, S.K., Tyler, D.S., Pappas, T.N., et al. (2007) Extended Resection for Pancreatic Adenocarcinoma. Oncologist, 12, 654-663. &lt;br&gt;https://doi.org/10.1634/theoncologist.12-6-654</mixed-citation></ref><ref id="hanspub.30275-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Pedrazzoli, S. (2015) Extent of Lymphadenectomy to Associate with Pancreaticoduodenectomy in Patients with Pancreatic Head Cancer for Better Tumor Staging. Cancer Treatment Reviews, 41, 577-587.  
&lt;br&gt;https://doi.org/10.1016/j.ctrv.2015.04.013</mixed-citation></ref><ref id="hanspub.30275-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, M., Cui, J.J., Wang, L.W., et al. (2017) Selection and Therapeutic Effect Evaluation of Chemotherapy Regimens for Pancreatic Cancer. Journal of Clinical Hepatology, 33, 53-56.</mixed-citation></ref><ref id="hanspub.30275-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Wiggans, R.G., Woolley, P.V., Macdonald, J.S., et al. (1978) Phase II Trial of Streptozotocin, Mitomycin-C and 5-Fluorouracil (SMF) in the Treatment of Advanced Pancreatic Cancer. Cancer, 41, 387-391.  
&lt;br&gt;https://doi.org/10.1002/1097-0142(197802)41:2&lt;387::AID-CNCR2820410201&gt;3.0.CO;2-X</mixed-citation></ref><ref id="hanspub.30275-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Carmichael, J. (1997) Clinical Response Benefit in Patients with Advanced Pancreatic Cancer. Role of Gemcitabine. Digestion, 58, 503-507. &lt;br&gt;https://doi.org/10.1159/000201493</mixed-citation></ref><ref id="hanspub.30275-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">郭双双, 王羽, 杨琼, 等. 吉西他滨联合5-FU或卡培他滨与吉西他滨单药治疗晚期胰腺癌对比的Meta分析[J]. 循证医学, 2006, 6(1): 42-47.</mixed-citation></ref><ref id="hanspub.30275-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Novarino, A., Chiappino, I., Bertelli, G.F., et al. (2004) Phase II Study of Cisplatin, Gemcitabine and 5-Fluorouracil in Advanced Pancreatic Cancer. Annals of Oncology, 15, 474-477. &lt;br&gt;https://doi.org/10.1093/annonc/mdh106</mixed-citation></ref><ref id="hanspub.30275-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Loehrer, P.J., Feng, Y., Cardenes, H., et al. (2011) Gemcitabine Alone versus Gemcitabine plus Radiotherapy in Patients with Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial. Journal of Clinical Oncology, 29, 4105-4112. &lt;br&gt;https://doi.org/10.1200/JCO.2011.34.8904</mixed-citation></ref><ref id="hanspub.30275-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Ng, S.P. and Herman, J.M. (2018) Stereotactic Radiotherapy and Particle Therapy for Pancreatic Cancer. Cancers (Basel), 10, pii: E75. &lt;br&gt;https://doi.org/10.3390/cancers10030075</mixed-citation></ref><ref id="hanspub.30275-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Schellenberg, D., Goodman, K.A., Lee, F., et al. (2008) Gemcitabine Chemotherapy and Single-Fraction Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer. In-ternational Journal of Radiation Oncology, Biology, Physics, 72, 678-686. &lt;br&gt;https://doi.org/10.1016/j.ijrobp.2008.01.051</mixed-citation></ref><ref id="hanspub.30275-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Mulvihill, S., Warren, R., Venook, A., et al. (2001) Safety and Feasibility of Injection with an E1B-55 kDa Gene-Deleted, Replication-Selective Adenovirus (ONYX-015) into Primary Carcinomas of the Pancreas: A Phase I Trial. Gene Therapy, 8, 308-315. &lt;br&gt;https://doi.org/10.1038/sj.gt.3301398</mixed-citation></ref><ref id="hanspub.30275-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Duda, D.G., Sunamura, M. and Lefter, L.P. (2003) Restoration of SMAD4 by Gene Therapy Reverses the Invasive Phenotype in Pancreatic Adenocarcinoma Cells. Oncogene, 22, 6857-6864. &lt;br&gt;https://doi.org/10.1038/sj.onc.1206751</mixed-citation></ref><ref id="hanspub.30275-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Xue, W., Chen, S.D., Yin, H., et al. (2014) CRISPR-Mediated Direct Mutation of Cancer Genes in the Mouse Live. Nature, 514, 380-384. &lt;br&gt;https://doi.org/10.1038/nature13589</mixed-citation></ref><ref id="hanspub.30275-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">van Dyke, T. and Jacks, T. (2002) Cancer Modeling in the Modern Era: Progress and Challenges. Cell, 108, 135-144.  
&lt;br&gt;https://doi.org/10.1016/S0092-8674(02)00621-9</mixed-citation></ref><ref id="hanspub.30275-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Jaffee, E.M., Hruban, R.H., Biedrzycki, B., et al. (2001) Novel Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Cancer: A Phase I Trial of Safety and Immune Activation. Journal of Clinical Oncology, 19, 145-156. &lt;br&gt;https://doi.org/10.1200/JCO.2001.19.1.145</mixed-citation></ref><ref id="hanspub.30275-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Bernhardt, S.L., Gjertsen, M.K., Trachsel, S., et al. (2006) Te-lomerase Peptide Vaccination of Patients with Non-Resectable Pancreatic Cancer: A Dose Escalating Phase I/II Study. British Journal of Cancer, 95, 1474-1482.  
&lt;br&gt;https://doi.org/10.1038/sj.bjc.6603437</mixed-citation></ref><ref id="hanspub.30275-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Copper, I.S. (1963) Cryogenic Surgery: A New Method of Destruction or Extirpation of Benign or Malignant Tissues. The New England Journal of Medicine, 268, 743-749. &lt;br&gt;https://doi.org/10.1056/NEJM196304042681401</mixed-citation></ref><ref id="hanspub.30275-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Clarke, D.M., Baust, J.M., Van Buskirk, R.G., et al. (2004) Addition of Anticancer Agents Enhances Freezing-Induced Prostate Cancer Cell Death: Implications of Mitochondrial Involvement. Cryobiology, 49, 45-61.  
&lt;br&gt;https://doi.org/10.1016/j.cryobiol.2004.05.003</mixed-citation></ref><ref id="hanspub.30275-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">李波, 李敬东, 陈晓理, 等. 无法切除的胰腺癌的冷冻手术治疗(附44例报告) [J]. 中华肝胆外科杂志, 2004, 10(8): 523-525.</mixed-citation></ref><ref id="hanspub.30275-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Kovach, S.J., Hendrickson, R.J., Cappadona, C.R., et al. (2002) Cryoablation of Unresectable Pancreatic Cancer Surgery. Surgery, 131, 463-464. &lt;br&gt;https://doi.org/10.1067/msy.2002.121231</mixed-citation></ref><ref id="hanspub.30275-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Ma, Y., Zou, F., Xiong, J., et al. (2015) Effect of Matrine on HPAC Cell Migration by Down-Regulating the Expression of MT1-MMP via Wnt Signaling. Cancer Cell International, 15, 59. &lt;br&gt;https://doi.org/10.1186/s12935-015-0210-4</mixed-citation></ref><ref id="hanspub.30275-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Singh, K., Dong, Q., Shanmugam, T., et al. (2018) Tetrandrine Inhibits Deregulated Cell Cycle in Pancreatic Cancer Cells: Differential Regulation of p21Cip1/Waf1, p27Kip1 and Cyclin D1. Cancer Letters, 425, 164-173.  
&lt;br&gt;https://doi.org/10.1016/j.canlet.2018.03.042</mixed-citation></ref><ref id="hanspub.30275-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Von Hoff, D.D., Ervin, T., Arena, F.P., et al. (2013) Increased Survival in Pancreatic Cancer with Nab-Paclitaxel plus Gemcitabine. The New England Journal of Medicine, 369, 1691-1703. &lt;br&gt;https://doi.org/10.1056/NEJMoa1304369</mixed-citation></ref><ref id="hanspub.30275-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">谢铮铮, 梁瑶, 孙路路. 厄洛替尼联合吉西他滨治疗胰腺癌有效性和安全性的Meta分析[J]. 中国临床药理学杂志, 2016, 32(8): 746-748.</mixed-citation></ref><ref id="hanspub.30275-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Moore, M.J., Goldstein, D., Hamm, J., et al. (2007) Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, 25, 1960-1966. &lt;br&gt;https://doi.org/10.1200/JCO.2006.07.9525</mixed-citation></ref></ref-list></back></article>